Combination of mTOR and MAPK Inhibitors—A Potential Way to Treat Renal Cell Carcinoma
Renal cell carcinoma (RCC) is the most common neoplasm that occurs in the kidney and is marked by a unique biology, with a long history of poor response to conventional cancer treatments. In the past few years, there have been significant advancements to understand the biology of RCC. This has led t...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2016-10-01
|
| Series: | Medical Sciences |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2076-3271/4/4/16 |
| _version_ | 1818682096033464320 |
|---|---|
| author | Ashutosh Chauhan Deepak Kumar Semwal Satyendra Prasad Mishra Sandeep Goyal Rajendra Marathe Ruchi Badoni Semwal |
| author_facet | Ashutosh Chauhan Deepak Kumar Semwal Satyendra Prasad Mishra Sandeep Goyal Rajendra Marathe Ruchi Badoni Semwal |
| author_sort | Ashutosh Chauhan |
| collection | DOAJ |
| description | Renal cell carcinoma (RCC) is the most common neoplasm that occurs in the kidney and is marked by a unique biology, with a long history of poor response to conventional cancer treatments. In the past few years, there have been significant advancements to understand the biology of RCC. This has led to the introduction of novel targeted therapies in the management of patients with metastatic disease. Patients treated with targeted therapies for RCC had shown positive impact on overall survival, however, no cure is possible and patients need to undergo treatment for long periods of time, which raises challenges to manage the associated adverse events. Moreover, many patients may not respond to it and even response may not last long enough in the responders. Many inhibitors of the Mammalian target of Rapamycin (mTOR) signaling pathway are currently being used in treatment of advanced RCC. Studies showed that inhibitions of mTOR pathways induce Mitogen-Activated Protein Kinase (MAPK) escape cell death and cells become resistant to mTOR inhibitors. Because of this, there is a need to inhibit both pathways with their inhibitors comparatively for a better outcome and treatment of patients with RCC. |
| first_indexed | 2024-12-17T10:13:24Z |
| format | Article |
| id | doaj.art-0dd34a977186405cb99f90e168f3680c |
| institution | Directory Open Access Journal |
| issn | 2076-3271 |
| language | English |
| last_indexed | 2024-12-17T10:13:24Z |
| publishDate | 2016-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medical Sciences |
| spelling | doaj.art-0dd34a977186405cb99f90e168f3680c2022-12-21T21:52:58ZengMDPI AGMedical Sciences2076-32712016-10-01441610.3390/medsci4040016medsci4040016Combination of mTOR and MAPK Inhibitors—A Potential Way to Treat Renal Cell CarcinomaAshutosh Chauhan0Deepak Kumar Semwal1Satyendra Prasad Mishra2Sandeep Goyal3Rajendra Marathe4Ruchi Badoni Semwal5Department of Urology, Postgraduate Institute of Medical Education & Research, Chandigarh 160012, IndiaDepartment of Phytochemistry, Faculty of Biomedical Sciences, Uttarakhand Ayurved University, Harrawala, Dehradun 248001, Uttarakhand, IndiaVice Chancellor, Uttarakhand Ayurved University, Harrawala, Dehradun 248001, Uttarakhand, IndiaDepartment of Hepatology, Postgraduate Institute of Medical Education & Research, Chandigarh 160012, IndiaDepartment of Pediatrics, Postgraduate Institute of Medical Education & Research, Chandigarh 160012, IndiaDepartment of Pharmaceutical Sciences, Tshwane University of Technology, Pretoria 0001, South AfricaRenal cell carcinoma (RCC) is the most common neoplasm that occurs in the kidney and is marked by a unique biology, with a long history of poor response to conventional cancer treatments. In the past few years, there have been significant advancements to understand the biology of RCC. This has led to the introduction of novel targeted therapies in the management of patients with metastatic disease. Patients treated with targeted therapies for RCC had shown positive impact on overall survival, however, no cure is possible and patients need to undergo treatment for long periods of time, which raises challenges to manage the associated adverse events. Moreover, many patients may not respond to it and even response may not last long enough in the responders. Many inhibitors of the Mammalian target of Rapamycin (mTOR) signaling pathway are currently being used in treatment of advanced RCC. Studies showed that inhibitions of mTOR pathways induce Mitogen-Activated Protein Kinase (MAPK) escape cell death and cells become resistant to mTOR inhibitors. Because of this, there is a need to inhibit both pathways with their inhibitors comparatively for a better outcome and treatment of patients with RCC.http://www.mdpi.com/2076-3271/4/4/16renal cell carcinomamammalian target of rapamycinmitogen activated protein kinasetarget therapy |
| spellingShingle | Ashutosh Chauhan Deepak Kumar Semwal Satyendra Prasad Mishra Sandeep Goyal Rajendra Marathe Ruchi Badoni Semwal Combination of mTOR and MAPK Inhibitors—A Potential Way to Treat Renal Cell Carcinoma Medical Sciences renal cell carcinoma mammalian target of rapamycin mitogen activated protein kinase target therapy |
| title | Combination of mTOR and MAPK Inhibitors—A Potential Way to Treat Renal Cell Carcinoma |
| title_full | Combination of mTOR and MAPK Inhibitors—A Potential Way to Treat Renal Cell Carcinoma |
| title_fullStr | Combination of mTOR and MAPK Inhibitors—A Potential Way to Treat Renal Cell Carcinoma |
| title_full_unstemmed | Combination of mTOR and MAPK Inhibitors—A Potential Way to Treat Renal Cell Carcinoma |
| title_short | Combination of mTOR and MAPK Inhibitors—A Potential Way to Treat Renal Cell Carcinoma |
| title_sort | combination of mtor and mapk inhibitors a potential way to treat renal cell carcinoma |
| topic | renal cell carcinoma mammalian target of rapamycin mitogen activated protein kinase target therapy |
| url | http://www.mdpi.com/2076-3271/4/4/16 |
| work_keys_str_mv | AT ashutoshchauhan combinationofmtorandmapkinhibitorsapotentialwaytotreatrenalcellcarcinoma AT deepakkumarsemwal combinationofmtorandmapkinhibitorsapotentialwaytotreatrenalcellcarcinoma AT satyendraprasadmishra combinationofmtorandmapkinhibitorsapotentialwaytotreatrenalcellcarcinoma AT sandeepgoyal combinationofmtorandmapkinhibitorsapotentialwaytotreatrenalcellcarcinoma AT rajendramarathe combinationofmtorandmapkinhibitorsapotentialwaytotreatrenalcellcarcinoma AT ruchibadonisemwal combinationofmtorandmapkinhibitorsapotentialwaytotreatrenalcellcarcinoma |